OnKure's drug candidate pipeline is highlighted by OKI-219, a selective PI3K alpha H1047R inhibitor for the treatment of certain types of breast cancer that began clinical trials in February 2024.

PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; ...

PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 - ...

Merger and Financing – As previously announced, the merger between OnKure, Inc. and Reneo Pharmaceuticals ... Research and development (R&D) expenses were $14.4 million for the fourth quarter ...

Feb. 3, 2025 — Maternal vitamin D levels in the first trimester were related to both prenatal growth and pregnancy outcomes, according to a new study. Low vitamin D levels during the first ...

What were the research and development expenses for Q4 2024? The R&D expenses for the fourth quarter of 2024 were $14.4 million, compared to $8.8 million in Q4 2023. Disclaimer: This is an AI ...